Clinical trials: Refractory Neoplasm
Relapsed, Refractory Multiple Myeloma
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.
- Trial name
- NCT04176380
- Testing
- RAPA-201 Autologous T cells
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Rapa Therapeutics LLC
Solid Tumor, Non Hodgkin Lymphoma
Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma
This is a Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination with PD-1 Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.
- Trial name
- NCT04775680
- Testing
- ADG106 injection, PD-1 antibody injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Adagene (Suzhou) Limited
Gynecological Cancer
A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer
This is a single-arm, open-label, phase Ib clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib in subjects with gynecological cancer, including 34 ovarian cancer，34 endometrial cancer，22 cervical…
- Trial name
- NCT04236362
- Testing
- TQB2450, Anlotinib
- Where
- 5 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ia: To observe the safety and tolerability of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of BL-M11D1.
- Trial name
- NCT05924750
- Testing
- BL-M11D1
- Where
- 8 sites in China
- Volunteers
- 130 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
CLL / SLL, CLL (Chronic Lymphocytic Leukemia)
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
This Phase 1, open-label, multicenter study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of lonitoclax (ZE50-0134) in adults with relapsed or refractory chronic…
- Conditions
- CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL)
- Trial name
- NCT06708897
- Testing
- Lonitoclax (ZE50-0134)
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Lomond Therapeutics Holdings, Inc.
Chronic Lymphocytic Leukemia
A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece
This study is being done to evaluate the clinical outcomes of Chronic Lymphocytic Leukemia (CLL) participants treated with venetoclax as routine standard of care in Greece.
- Trial name
- NCT04159779
- Where
- 21 sites in Greece
- Volunteers
- 180 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
The purpose of this study is to determine the maximum-tolerated dose (MTD) of dinaciclib therapy in combination with rituximab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Trial name
- NCT01650727
- Testing
- Dinaciclib, Rituximab
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Pancreatic Neuroendocrine Tumor
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer cells, in patients with advanced…
- Conditions
- Solid Tumor, Pancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
- Trial name
- NCT02355535
- Testing
- PAC-1
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Vanquish Oncology, Inc.
Hepatocellular Carcinoma, Metastatic Cancer
GEN2 Directed Cancer Immunotherapy Trial
Phase 1, non-randomized, open label dose escalation clinical trial evaluating the safety of GEN2 in participants with primary \& metastatic liver tumors.
- Trial name
- GEN2 (NCT04313868)
- Testing
- GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
- Where
- 4 sites in Philippines
- Volunteers
- 61 people
- Sponsor
- GenVivo, Inc.
Relapsed or Refractory Peripheral T-cell Lymphoma
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
- Trial name
- NCT05833724
- Testing
- Chidamide
- Where
- 6 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
B-Cell Non-Hodgkin Lymphoma (B-NHL)
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to…
- Trial name
- OLYMPIA-4 (NCT06230224)
- Testing
- Odronextamab, Ifosfamide, Carboplatin
- Where
- 81 sites in Argentina, Australia and 12 more
- Volunteers
- 216 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404 as a single or multiple dose, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple…
- Trial name
- NCT02278315
- Testing
- I-131-CLR1404, dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Cellectar Biosciences, Inc.
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Rationale: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known if vaccine therapy is effective for prostate cancer.
- Trial name
- NCT00005947
- Testing
- sipuleucel-T
- Where
- 34 sites in United States
- Volunteers
- 127 people
- Sponsor
- Dendreon
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small…
- Trial name
- NCT01611090
- Testing
- Ibrutinib, Bendamustine hydrochloride, Rituximab
- Where
- 155 sites in United States, Argentina and 19 more
- Volunteers
- 578 people
- Sponsor
- Janssen Research & Development, LLC
B-Cell Non-Hodgkin Lymphoma
A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This is an open-label, first-in-human dose escalation and dose expansion Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HP-002 in patients with relapsed or refractory…
- Trial name
- NCT07658352
- Testing
- HP-002
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Shanghai Helioson Pharmaceutical Co., Ltd.
Multiple Myeloma, Renal Insufficiency
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
The purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).
- Trial name
- NCT00721734
- Testing
- Carfilzomib
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amgen
Relapsed/Refractory Multiple Myeloma
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT07454187
- Testing
- SG2918
- Where
- 4 sites in China
- Volunteers
- 40 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Differentiated Thyroid Cancer (DTC)
A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China
The primary purpose of this study is to compare the progression-free survival (PFS) of participants with radioiodine (131 I)-refractory differentiated thyroid cancer (DTC) and radiographic evidence of disease progression within…
- Trial name
- NCT02966093
- Testing
- Lenvatinib
- Where
- 24 sites in China
- Volunteers
- 151 people
- Sponsor
- Eisai Co., Ltd.
Leukemia, Myeloid, Acute
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML…
- Trial name
- NCT03388749
- Testing
- Liposomal Annamycin
- Where
- 5 sites in Poland
- Volunteers
- 20 people
- Sponsor
- Moleculin Biotech, Inc.
Relapsed/Refractory Multiple Myeloma
Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP
Multicentre, open label, uncontrolled, phase I pharmacokinetic study, to determine the Maximum Tolerated Dose (MTD) of APO010 administered intravenously on D1, D8 and D15 followed by a one-week drug rest, in patients with…
- Trial name
- SMR-3184 (NCT03196947)
- Testing
- APO010
- Where
- Denmark
- Volunteers
- 1 people
- Sponsor
- Allarity Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.